Facilitated By

San Antonio Medical Foundation

A Randomized, Double-Blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination withAzacitidine or Decitabine in the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Henry Jackson Foundation
Research Start Date
Status
Active

This is a randomized, double-blind, placebo-controlled phase 3 study designed to compare the OS between patients treated with HMA plus vadastuximab talirine (experimental arm) versus patients treated with HMA plus placebo (comparator arm). Patients will be randomized in a 1:1 manner to one of the study arms. Investigators may select either HMA (azacitidine or decitabine).

Clinical Care
Cancer
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.